EP0794802B1 - Complexe d'inclusion d'un acide gras radiohalogene dans une cyclodextrine - Google Patents
Complexe d'inclusion d'un acide gras radiohalogene dans une cyclodextrine Download PDFInfo
- Publication number
- EP0794802B1 EP0794802B1 EP95940305A EP95940305A EP0794802B1 EP 0794802 B1 EP0794802 B1 EP 0794802B1 EP 95940305 A EP95940305 A EP 95940305A EP 95940305 A EP95940305 A EP 95940305A EP 0794802 B1 EP0794802 B1 EP 0794802B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cyclodextrin
- fatty acid
- radiohalogenated
- composition according
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the radiohalogenated fatty acids used in the inclusion complex can also be of different types.
- the metabolism of fatty acid by ⁇ -oxidation can be slowed down by the presence of ⁇ position of one or two methyl.
- the afterglow time fatty acid in the myocardial cell is so increased, making it possible to perform the exam scintigraphic with more comfort.
- Additives used for this purpose can be tampons, saline, and especially polyols.
- polyols usable we can cite mannitol, inositol, sorbitol and dixylitol.
- Examples 1 to 4 Solubilization of 16-iodo 3-methyl hexadecanoic acid in different cyclodextrins.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
Description
- un acide gras bromé ou iodé, non radioactif,
- un solvant organique tel que l'acétone,
- un iodure métallique, tel que l'iodure de sodium,
- une cyclodextrine, et
- un excipient convenant à la préparation d'une solution injectable.
Claims (18)
- Composition radiopharmaceutique comprenant un acide gras radiohalogéné, caractérisé en ce que l'acide gras radiohalogéné est sous la forme d'un complexe d'inclusion avec une cyclodextrine.
- Composition radiopharmaceutique selon la revendication 1, caractérisée en ce que la cyclodextrine est une β-cyclodextrine, une γ-cyclodextrine ou un dérivé de celles-ci.
- Composition selon la revendication 2, caractérisée en ce que la cyclodextrine est l'heptakis-2,6-di-O-méthyl-cyclo-maltoheptaose.
- Composition selon la revendication 2, caractérisée en ce que la cyclodextrine est l'heptakis-O-hydoxypropyl cyclomaltoheptaose.
- Composition selon l'une quelconque des revendications 1 à 4, caractérisée en ce que l'acide gras est un acide gras ω-radiohalogéné aliphatique comprenant de 14 à 18 atomes de carbone, qui est éventuellement mono ou disubstitué en position β par un ou deux groupes alkyle, ou un acide gras aromatique.
- Composition selon l'une quelconque des revendications 1 à 5, caractérisée en ce que l'halogène radioactif de l'acide gras est choisi parmi les isotopes radioactifs de F, Cl, Br et I.
- Composition selon la revendication 6, caractérisée en ce que l'halogène est 123I, 125I, 131I ou 124I.
- Composition selon l'une quelconque des revendications 1 à 7, caractérisée en ce que l'acide gras est l'acide 16-iodo 3-méthyl hexadécanoïque.
- Composition radiopharmaceutique selon l'une quelconque des revendications 1 à 8, caractérisée en ce qu'elle est constituée par une solution aqueuse du complexe d'inclusion de la cyclodextrine et de l'acide gras radiohalogéné.
- Composition radiopharmaceutique selon la revendication 9, caractérisée en ce qu'elle comprend au moins un autre additif pour amener l'osmolarité de la solution aqueuse à une valeur adaptée à l'injection.
- Composition radiopharmaceutique selon la revendication 10, caractérisée en ce que l'additif est l'inositol ou le mannitol.
- Procédé de préparation d'une composition radiopharmaceutique selon l'une quelconque des revendications 1 à 11, caractérisé en ce qu'il consiste à mélanger l'acide gras radiohalogéné amené à sec avec une solution aqueuse de cyclodextrine.
- Procédé selon la revendication 12, caractérisé en ce que l'on soumet la solution obtenue à une stérilisation par chauffage.
- Procédé selon l'une quelconque des revendications 12 et 13, caractérisé en ce qu'on utilise des quantités d'acide gras radiohalogéné et de cyclodextrine telles que le rapport molaire de la cyclodextrine à l'acide gras radiohalogéné soit de 2 à 10.
- Procédé selon l'une quelconque des revendications 12 et 14, caractérisé en ce que la solution aqueuse de cyclodextrine comprend un additif choisi parmi les tampons et les polyols pour régler l'osmolarité de la solution.
- Procédé selon la revendication 13, caractérisé en ce que l'additif est un polyol.
- Procédé selon la revendication 16, caractérisé en ce que l'additif est l'inositol ou le mannitol.
- Trousse pour la préparation d'une composition radiopharmaceutique à l'iode radioactif, selon l'une quelconque des revendications 1 à 11, caractérisée en ce qu'elle comprend au moins deux flacons qui contiennent respectivement un seul ou plusieurs des constituants suivants:un acide gras iodé ou bromé non radioactif,un solvant organique,un iodure métallique,une cyclodextrine, etun excipient convenant à la préparation d'une solution injectable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9413609A FR2726765B1 (fr) | 1994-11-14 | 1994-11-14 | Compositions radiopharmaceutiques comprenant un complexe d'inclusion d'une cyclodextrine et d'un acide gras radiohalogene |
FR9413609 | 1994-11-14 | ||
PCT/FR1995/001489 WO1996014881A1 (fr) | 1994-11-14 | 1995-11-13 | Complexe d'inclusion d'un acide gras radiohalogene dans une cyclodextrine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0794802A1 EP0794802A1 (fr) | 1997-09-17 |
EP0794802B1 true EP0794802B1 (fr) | 2002-02-27 |
Family
ID=9468773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95940305A Expired - Lifetime EP0794802B1 (fr) | 1994-11-14 | 1995-11-13 | Complexe d'inclusion d'un acide gras radiohalogene dans une cyclodextrine |
Country Status (6)
Country | Link |
---|---|
US (1) | US5993776A (fr) |
EP (1) | EP0794802B1 (fr) |
AT (1) | ATE213650T1 (fr) |
DE (1) | DE69525647T2 (fr) |
FR (1) | FR2726765B1 (fr) |
WO (1) | WO1996014881A1 (fr) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2508902B1 (fr) * | 1981-07-02 | 1985-09-06 | Commissariat Energie Atomique | Procede de preparation extemporanee d'un acide gras injectable, marque a l'iode radioactif et preparation de derives iodes utilisables pour la mise en oeuvre de ce procede |
WO1985000753A1 (fr) * | 1983-08-17 | 1985-02-28 | Mallinckrodt, Inc. | Composes chimiques |
CA1221105A (fr) * | 1983-09-16 | 1987-04-28 | Alfred H. Dougan | Acides gras halogenes en position omega |
DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
US5068226A (en) * | 1987-12-07 | 1991-11-26 | Cyclex, Inc. | Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
US5068227A (en) * | 1989-01-18 | 1991-11-26 | Cyclex, Inc. | Cyclodextrins as carriers |
US5321014A (en) * | 1991-06-28 | 1994-06-14 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular encapsulation and delivery of alkenes alkynes and long chain alkanes, to living mammalian cells |
US5300280A (en) * | 1992-02-14 | 1994-04-05 | Mallinckrodt Medical, Inc. | Stabilized radiopharmaceutical kits |
JP2715240B2 (ja) * | 1993-05-18 | 1998-02-18 | 株式会社第一ラジオアイソトープ研究所 | 放射性ヨウ素標識脂肪酸−シクロデキストリン複合体およびこれを含有するイメージング剤 |
GB9325330D0 (en) * | 1993-12-10 | 1994-02-16 | Univ Toronto | Fluorocyclodextrin drug delivery system |
-
1994
- 1994-11-14 FR FR9413609A patent/FR2726765B1/fr not_active Expired - Fee Related
-
1995
- 1995-11-13 AT AT95940305T patent/ATE213650T1/de not_active IP Right Cessation
- 1995-11-13 US US08/836,196 patent/US5993776A/en not_active Expired - Fee Related
- 1995-11-13 WO PCT/FR1995/001489 patent/WO1996014881A1/fr active IP Right Grant
- 1995-11-13 EP EP95940305A patent/EP0794802B1/fr not_active Expired - Lifetime
- 1995-11-13 DE DE69525647T patent/DE69525647T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FR2726765B1 (fr) | 1996-12-20 |
US5993776A (en) | 1999-11-30 |
DE69525647T2 (de) | 2002-10-17 |
EP0794802A1 (fr) | 1997-09-17 |
ATE213650T1 (de) | 2002-03-15 |
DE69525647D1 (de) | 2002-04-04 |
WO1996014881A1 (fr) | 1996-05-23 |
FR2726765A1 (fr) | 1996-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5284831A (en) | Drug delivery porphyrin compositions and methods | |
RU2403067C2 (ru) | СТАБИЛИЗИРОВАННЫЕ КОМПОЗИЦИИ ТЕХНЕЦИЯ-99m (99mTc) | |
EP0419387A1 (fr) | Nouveaux dérivés hydrophiles, application au diagnostic et à la thérapeutique, kits diagnostiques ou thérapeutiques et réactifs immunologiques | |
Awasthi et al. | Synthesis and in vivo evaluation of p-18F-Fluorohippurate as a new radiopharmaceutical for assessment of renal function by PET | |
Lipowska et al. | First evaluation of a 99mTc-tricarbonyl complex, 99mTc (CO) 3 (LAN), as a new renal radiopharmaceutical in humans | |
JP5325779B2 (ja) | 医薬組成物 | |
EP0794802B1 (fr) | Complexe d'inclusion d'un acide gras radiohalogene dans une cyclodextrine | |
US4042677A (en) | Technetium-99m labeled radiodiagnostic agents and method of preparation | |
FR2919189A1 (fr) | Nouvelles compositions a base de polyosides greffes par des composes polyamines ou polysoufres. | |
FR2679452A1 (fr) | Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation. | |
Li et al. | Preparation and validation of cyclodextrin-based excipients for radioiodinated hypericin applied in a targeted cancer radiotherapy | |
EP2536438B1 (fr) | Composition pour le traitement du cancer du foie chez l'homme a base de rhenium-188 et procede de preparation d'une telle composition | |
US6541514B2 (en) | Process for the manufacture of 117Sn diethylenetriaminepentaacetic acids | |
FR2835434A1 (fr) | Utilisation cosmetique ou dermatologique de la vitamine a ou de ses esters, en association avec une beta-cyclodextrine partiellement methylee | |
JP2715240B2 (ja) | 放射性ヨウ素標識脂肪酸−シクロデキストリン複合体およびこれを含有するイメージング剤 | |
EP4124361B1 (fr) | Ligands macrocycliques avec groupement(s) picolinate(s), leurs complexes ainsi que leurs utilisations medicales | |
EP3733216A1 (fr) | Solution d'astate et son procédé de production | |
US6127530A (en) | Method for the reduction of oxygenated compounds of rhenium or technetium | |
FR2733753A1 (fr) | Derives iodes de monosaccharides utilisables comme produits radiopharmaceutiques | |
JPH0623114B2 (ja) | 放射性医薬品とその調製用高分子化合物 | |
Khaw et al. | Re: Concerning the Labeling of DTPA-Coupled Proteins with Tc-99m—Reply | |
BE853515A (fr) | Nouveaux agents radiodiagnostiques marques au technetium-99m pour l'exploration du foie et de la moelle osseuse et leur procede de preparation | |
JPH0219328A (ja) | 安定な放射線診断製品およびその製造法 | |
Riou et al. | Differential effects of cyclodextrins and derivatives on the biological behavior of the myocardial perfusion imaging agent 99mTcN-NOET | |
Lepareur | Active and passive vectorization of technetium {sup 99m} and {sup 188} rhenium radiopharmaceuticals for medical imaging and radiotherapy; Vectorisations active et passive de radiopharmaceutiques du technetium-99m et du rhenium-188 pour l'imagerie medicale et la therapie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970428 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 20010119 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020227 |
|
REF | Corresponds to: |
Ref document number: 213650 Country of ref document: AT Date of ref document: 20020315 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69525647 Country of ref document: DE Date of ref document: 20020404 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020527 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20020502 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20021130 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20021128 |
|
BERE | Be: lapsed |
Owner name: *CIS BIO INTERNATIONAL Effective date: 20021130 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20031013 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20031015 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20031016 Year of fee payment: 9 Ref country code: CH Payment date: 20031016 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20031022 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20031027 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050601 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050601 |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20041113 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050729 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20050601 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051113 |